Etoricoxib

SKU: orb1308128

Description

Etoricoxib (MK-663) is a selective COX-2 inhibitor NSAID used in research for its analgesic and anti-inflammatory properties. Studies investigate its potential antineoplastic effects, including the inhibition of tumor cell proliferation and angiogenesis, in both in vitro and in vivo models.

Research Area

Immunology & Inflammation, Neuroscience

Key Properties

• CAS Number: 202409-33-4
• MW: 358.84
• Purity: 99.87% (May vary between batches)
• Formula: C₁₈H₁₅ClN₂O₂S
• SMILES: CC1=NC=C(C=C1)C1=NC=C(Cl)C=C1C1=CC=C(C=C1)S(C)(=O)=O
• Target: COX
• Solubility: DMSO:252 mg/mL (702.26 mM);H2O:< 1 mg/mL (insoluble or slightly soluble);10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (13.93 mM);Ethanol:43 mg/mL (119.83 mM)

Bioactivity

• Target IC50:
  COX-1:116 μM (in human whole blood)|COX-2:1.1 μM COX-1
• In Vivo:
  The preferential cyclooxygenase-2 inhibitor etoricoxib significantly reduces the anticonvulsant action of phenytoin and significantly increases the beneficial action of diazepam against maximal electroshock and pentylenetetrazole-induced convulsions in a mouse model. Etoricoxib has the potential to act as an anti-apoptotic and anti- proliferative agent in the colon.
• Cell Research:
  Human colon carcinoma cell line HCT-116 are treated with various coxibs for 2 h. Subsequently, the cells are harvested and the sphingolipids isolated and determined by LC-MS/MS. (Only for Reference)

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

MK0663, MK-0663, MK 663, MK 0663, Nucoxia, MK663, MK-663, inhibit, L 791456, Etoricoxib, L791456, L-791456, Inhibitor, Arcoxia, Desvenlafaxine, COX, Cyclooxygenase, Tauxib

Compound Identifiers

PubChem CID

123619